A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 with BIBF 1120 in Patients with Advanced Solid Tumors.

Trial Profile

A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 with BIBF 1120 in Patients with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2009

At a glance

  • Drugs Afatinib; Nintedanib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 24 to 28 as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top